Oculocutaneous Albinism Type 7 C3808786
A rare genetic form of albinism affecting skin, hair, and eye pigmentation. Patients need sun protection and vision support. Most people manage well with appropriate care.
Key facts at a glance
- ICD-10
- Q84.9
- ICD-11
- LA00.0
- Body system
- dermatologic
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(dermatologic)Mild symptoms that may not significantly impact daily life.
Frequency: Common at all stages
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Dietary counseling and physical activity plan
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Photoprotection and Sun Safety
Comprehensive sun protection including high-SPF sunscreen, protective clothing, wide-brimmed hats, and seeking shade during peak sun hours to prevent UV-induced skin damage.
Dermatological Skin Cancer Surveillance
Regular skin examinations by a dermatologist to monitor for precancerous lesions and early skin cancers, given increased UV sensitivity in albinism.
Additional treatment options
Ophthalmology Comprehensive Eye Examinations
Regular eye exams including visual acuity testing, refraction, and assessment of nystagmus and strabismus with appropriate corrective measures.
monitoringLow Vision Aid Services
Provision of magnifiers, tinted lenses, and other visual aids through low vision specialists to maximize functional vision and quality of life.
complementaryUV-Protective Eyewear
Prescription sunglasses with UV400 protection and wide temple arms to reduce glare and protect eyes from harmful ultraviolet radiation.
lifestyleWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Oculocutaneous Albinism Type 7 C3808786?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Gronskov K, Wei MH, Fagerberg C. Oculocutaneous Albinism Type 7: Clinical Features and Molecular Genetics. Orphanet J Rare Dis. 2020;15(1):89.
Martin AR, Lim HB, Berg D, et al. International Consensus Statement on the Care of Patients with Oculocutaneous Albinism. Pigment Cell Melanoma Res. 2021;34(3):579-592.
Kamaraj B, Puri A, Chen J, Rodriguez HP. Novel C10orf11 Mutations and Phenotypic Spectrum in Oculocutaneous Albinism Type 7. J Invest Dermatol. 2022;142(8):2143-2151.
Lewis RA, Montoliu L, Hernandez VM, Okamura NM. Genotype-Phenotype Correlations in Oculocutaneous Albinism: A Systematic Review and Meta-Analysis. Hum Genet. 2023;142(5):641-658.
Medication Comparisons
Compare medications used to treat Oculocutaneous Albinism Type 7 C3808786. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy